These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37330416)

  • 21. Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.
    Brogi S; Ibba R; Rossi S; Butini S; Calderone V; Gemma S; Campiani G
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of Dually Activated Michael Acceptor to the Rational Design of Reversible Covalent Inhibitor for Enterovirus 71 3C Protease.
    Ma Y; Li L; He S; Shang C; Sun Y; Liu N; Meek TD; Wang Y; Shang L
    J Med Chem; 2019 Jul; 62(13):6146-6162. PubMed ID: 31184893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity.
    Ma C; Xia Z; Sacco MD; Hu Y; Townsend JA; Meng X; Choza J; Tan H; Jang J; Gongora MV; Zhang X; Zhang F; Xiang Y; Marty MT; Chen Y; Wang J
    J Am Chem Soc; 2021 Dec; 143(49):20697-20709. PubMed ID: 34860011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can Cysteine Protease Cross-Class Inhibitors Achieve Selectivity?
    Cianni L; Feldmann CW; Gilberg E; Gütschow M; Juliano L; Leitão A; Bajorath J; Montanari CA
    J Med Chem; 2019 Dec; 62(23):10497-10525. PubMed ID: 31361135
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploring the Mechanism of Covalent Inhibition: Simulating the Binding Free Energy of α-Ketoamide Inhibitors of the Main Protease of SARS-CoV-2.
    Mondal D; Warshel A
    Biochemistry; 2020 Dec; 59(48):4601-4608. PubMed ID: 33205654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors.
    Shunmugam L; Ramharack P; Soliman MES
    Protein J; 2017 Oct; 36(5):397-406. PubMed ID: 28815420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.
    Chen D; Frezza M; Schmitt S; Kanwar J; Dou QP
    Curr Cancer Drug Targets; 2011 Mar; 11(3):239-53. PubMed ID: 21247388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ubiquitin-based anticancer therapy: carpet bombing with proteasome inhibitors vs surgical strikes with E1, E2, E3, or DUB inhibitors.
    Mattern MR; Wu J; Nicholson B
    Biochim Biophys Acta; 2012 Nov; 1823(11):2014-21. PubMed ID: 22610084
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
    Hirose Y; Shindo N; Mori M; Onitsuka S; Isogai H; Hamada R; Hiramoto T; Ochi J; Takahashi D; Ueda T; Caaveiro JMM; Yoshida Y; Ohdo S; Matsunaga N; Toba S; Sasaki M; Orba Y; Sawa H; Sato A; Kawanishi E; Ojida A
    J Med Chem; 2022 Oct; 65(20):13852-13865. PubMed ID: 36229406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles.
    Hossam M; Lasheen DS; Abouzid KA
    Arch Pharm (Weinheim); 2016 Aug; 349(8):573-93. PubMed ID: 27258393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The spectrum between substrates and inhibitors: Pinpointing the binding mode of dengue protease ligands with modulated basicity and hydrophobicity.
    Dražić T; Kühl N; Gottscheber N; Hacker CN; Klein CD
    Bioorg Med Chem; 2021 Oct; 48():116412. PubMed ID: 34592636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance.
    Schwartz PA; Kuzmic P; Solowiej J; Bergqvist S; Bolanos B; Almaden C; Nagata A; Ryan K; Feng J; Dalvie D; Kath JC; Xu M; Wani R; Murray BW
    Proc Natl Acad Sci U S A; 2014 Jan; 111(1):173-8. PubMed ID: 24347635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large library docking for novel SARS-CoV-2 main protease non-covalent and covalent inhibitors.
    Fink EA; Bardine C; Gahbauer S; Singh I; Detomasi TC; White K; Gu S; Wan X; Chen J; Ary B; Glenn I; O'Connell J; O'Donnell H; Fajtová P; Lyu J; Vigneron S; Young NJ; Kondratov IS; Alisoltani A; Simons LM; Lorenzo-Redondo R; Ozer EA; Hultquist JF; O'Donoghue AJ; Moroz YS; Taunton J; Renslo AR; Irwin JJ; García-Sastre A; Shoichet BK; Craik CS
    Protein Sci; 2023 Aug; 32(8):e4712. PubMed ID: 37354015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis, and
    Corrigan TS; Lotti Diaz LM; Border SE; Ratigan SC; Kasper KQ; Sojka D; Fajtova P; Caffrey CR; Salvesen GS; McElroy CA; Hadad CM; Doğan Ekici Ö
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1387-1402. PubMed ID: 32633155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of P. falciparum dipeptidyl aminopeptidase 3 specificity identifies differences in amino acid preferences between peptide-based substrates and covalent inhibitors.
    de Vries LE; Sanchez MI; Groborz K; Kuppens L; Poreba M; Lehmann C; Nevins N; Withers-Martinez C; Hirst DJ; Yuan F; Arastu-Kapur S; Horn M; Mares M; Bogyo M; Drag M; Deu E
    FEBS J; 2019 Oct; 286(20):3998-4023. PubMed ID: 31177613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
    Gao S; Sylvester K; Song L; Claff T; Jing L; Woodson M; Weiße RH; Cheng Y; Schäkel L; Petry M; Gütschow M; Schiedel AC; Sträter N; Kang D; Xu S; Toth K; Tavis J; Tollefson AE; Müller CE; Liu X; Zhan P
    J Med Chem; 2022 Oct; 65(19):13343-13364. PubMed ID: 36107752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new method for filtering of reactive "warheads" of transition-state analog protease inhibitors.
    Traube T; Shokhen M; Albeck A
    Eur J Med Chem; 2014 Apr; 77():134-8. PubMed ID: 24631732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit.
    Blackburn C; Gigstad KM; Hales P; Garcia K; Jones M; Bruzzese FJ; Barrett C; Liu JX; Soucy TA; Sappal DS; Bump N; Olhava EJ; Fleming P; Dick LR; Tsu C; Sintchak MD; Blank JL
    Biochem J; 2010 Sep; 430(3):461-76. PubMed ID: 20632995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
    Baillie TA
    Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations.
    Mihalovits LM; Ferenczy GG; Keserű GM
    J Chem Inf Model; 2020 Dec; 60(12):6579-6594. PubMed ID: 33295760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.